Baseline characteristics comparing the two arms of the trial
| Variable | Group* | p Value | ||
|---|---|---|---|---|
| Guidelines (n = 56) | Decision aid (n = 53) | |||
| *Summary statistics are mean (and standard deviation) or number (and %). | ||||
| RR, relative risk. | ||||
| Age (years) | 73.7 (6.2) | 73.1 (6.7) | Mean diff −0.7 (−3.1, 1.8) | 0.60 |
| Female, n (%) | 25/56 (44.6%) | 23/53 (43.4%) | RR 0.97 (0.64, 1.49) | 1.00 |
| Annual % risk of stroke | 2.13 (1.02) | 2.19 (1.39) | Mean diff 0.06 (−0.40, 0.52) | 0.79 |
| Risk of bleed on warfarin | 1.59 (0.51) | 1.53 (0.55) | Mean diff −0.06 (−0.26, 0.14) | 0.56 |
| Definite pre-clinic preference for warfarin: n (%) | 33/55 (60.0%) | 29/53 (54.7%) | RR 0.91 (0.66, 1.26) | 0.70 |
| Participants already taking warfarin, n (%) | 40/56 (71.4%) | 37/53 (69.8%) | RR 0.98 (0.78, 1.25) | 1.00 |
| Participants already taking aspirin, n (%) | 11/53 (20.8%) | 14/50 (28.0%) | RR 1.35 (0.68, 2.69) | 0.49 |